本研究的目的是评估先前报道的肺癌生存率改善是否在不同诊断年龄和不同肺癌亚型之间一致。获得了 1990 年至 2016 年间丹麦、芬兰、冰岛、挪威和瑞典诊断出的肺癌数据来自 NORDCAN 数据库。灵活的参数模型用于估计按性别划分的年龄标准化和年龄特异性相对生存率，以及参考调整的粗死亡概率和生命年损失。年龄标准化生存率也根据三种主要亚型进行估计；腺癌、鳞状细胞癌和小细胞癌。所有国家的 1 年和 5 年相对生存率均持续改善。不同年龄组和不同亚型的改善模式相似。丹麦的生存率改善最大，而芬兰的改善相对较小。在最近一段时期，年龄标准化的 5 年相对生存率估计范围为 13% 至 26%，因肺癌死亡的 5 年粗概率范围为 73% 至 85%。在所有北欧国家中，生存率随着年龄的增长而下降，男性和小细胞癌的生存率较低。自 1990 年以来，女性和男性以及各个年龄段的肺癌生存率都有了显着提高。所有主要亚型都出现了改善。然而，肺癌的生存率仍然很低，四分之三的患者在诊断后五年内死于肺癌。版权所有 © 2024 作者。由 Elsevier B.V. 出版。保留所有权利。

The aim of this study was to evaluate if the previously reported improvements in lung cancer survival were consistent across age at diagnosis and by lung cancer subtypes.Data on lung cancers diagnosed between 1990 and 2016 in Denmark, Finland, Iceland, Norway and Sweden were obtained from the NORDCAN database. Flexible parametric models were used to estimate age-standardized and age-specific relative survival by sex, as well as reference-adjusted crude probabilities of death and life-years lost. Age-standardised survival was also estimated by the three major subtypes; adenocarcincoma, squamous cell and small-cell carcinoma.Both 1- and 5-year relative survival improved continuously in all countries. The pattern of improvement was similar across age groups and by subtype. The largest improvements in survival were seen in Denmark, while improvements were comparatively smaller in Finland. In the most recent period, age-standardised estimates of 5-year relative survival ranged from 13% to 26% and the 5-year crude probability of death due to lung cancer ranged from 73% to 85%. Across all Nordic countries, survival decreased with age, and was lower in men and for small-cell carcinoma.Lung cancer survival has improved substantially since 1990, in both women and men and across age. The improvements were seen in all major subtypes. However, lung cancer survival remains poor, with three out of four patients dying from their lung cancer within five years of diagnosis.Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.